治疗抗中性粒细胞胞质抗体相关血管炎新药阿伐可泮  

A new drug for the treatment of anti⁃neutrophil cytoplasmic antibody associated vasculitis:avacopan

作　　者：赵建群 靳会欣[2] 吴梦冉[3] 马银玲 庞国勋[2] 吴玉佩[2] ZHAO Jian-qun;JIN Hui-xin;WU Meng-ran;MA Yin-ling;PANG Guo-xun;WU Yu-pei(Graduate School,Hebei Medical University,Shijiazhuang 050051,China;Department of Pharmacy,Hebei General Hospital,Shijiazhuang 050051,China;Shijiazhuang People's Hospital,Shijiazhuang 050051,China)

机构地区：[1]河北医科大学研究生学院,石家庄050051 [2]河北省人民医院药学部,石家庄050051 [3]石家庄市人民医院,石家庄050051

出　　处：《中国新药杂志》2024年第17期1752-1755,共4页Chinese Journal of New Drugs

基　　金：河北省2021年度医学科学研究课题计划项目(20211559)。

摘　　要：阿伐可泮是一款口服选择性补体C5a受体(C5a receptor,C5aR)抑制剂,于2021年10月被美国FDA批准,用于与标准疗法(糖皮质激素)联合治疗抗中性粒细胞胞浆自身抗体相关性血管炎。临床研究表明,阿伐可泮可以显著减少治疗抗中性粒细胞胞质抗体相关血管炎所用糖皮质激素剂量,降低皮质类固醇相关毒性,改善疾病预后。现对阿伐可泮的作用机制、药动学、临床研究、安全性等进行概述,以期为临床应用提供参考。Avacopan is an oral selective complement C5a receptor(C5aR)inhibitor that was approved by the FDA in October 2021 for the treatment of anti⁃neutrophil cytoplasmic autoantibody associated vasculitis in combination with standard therapy(glucocorticoids).Clinical studies have shown that avacopan can significantly reduce the dose of glucocorticoids used in the treatment of anti⁃neutrophil cytoplasmic antibody associated vasculitis,reduce corticosteroid⁃related toxicity,and improve the prognosis of the disease.This article summarizes the mechanism of action,pharmacokinetics,clinical studies and safety of avacopan,aiming to provide references for clinical application.

关 键 词：阿伐可泮 选择性补体C5a受体抑制剂 抗中性粒细胞胞质抗体相关血管炎 

分 类 号：R972[医药卫生—药品]